Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dexin Yu

Showing results (221-230 of 221) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 221 results.
The Lancet. Oncology|September 4, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Pengfei Shen, Juan Li, et al.
Pageof 23

Showing results (221-230 of 221) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 221 results.
The Lancet. Oncology|September 4, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Pengfei Shen, Juan Li, et al.
Pageof 23